Evidence map›Paper›PMID 24842625›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2014

Continued rapid increase in thyroid cancer incidence in california: trends by patient, tumor, and neighborhood characteristics.

Pamela L Horn-Ross, Daphne Y Lichtensztajn, Christina A Clarke, Chrysoula Dosiou, Ingrid Oakley-Girvan, Peggy Reynolds, Scarlett Lin Gomez, David O Nelson

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Liver Cancer Incidence and Area-Level Geographic Disparities in Pennsylvania-A Geo-Additive Approach.International journal of environmental research and public health · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Pamela L Horn-RossAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California pam@cpic.org.
Daphne Y LichtensztajnAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Christina A ClarkeAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Chrysoula DosiouAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Ingrid Oakley-GirvanAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Peggy ReynoldsAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Scarlett Lin GomezAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CaliforniaAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
David O NelsonAuthors' Affiliations: Cancer Prevention Institute of California, Fremont; Division of Epidemiology, Department of Health Research and Policy and Division of Endocrinology, Department of Medicine; and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.

Funding

CALIFORNIA COORDINATED CANCER PREVENTION & CONTROL PROGRAMU58DP003862 · DP · CALIFORNIA STATE DEPT OF PUBLIC HEALTH · PI SNIPES, KURT P · 2012 to 2014
$31.5M
NCCDPHP CDC HHS U58 DP003862NCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000140CNCI NIH HHS N01 PC035136NCI NIH HHS N02 PC015105
6 · The paper itself

Abstract

backgroundThyroid cancer incidence is increasing worldwide. Incorporating 22 years of incidence data through 2009, we extend examination of these trends among a wide array of subgroups defined by patient (age, sex, race/ethnicity, and nativity), tumor (tumor size and stage), and neighborhood (socioeconomic status and residence in ethnic enclaves) characteristics, to identify possible reasons for this increase.

methodsThyroid cancer incidence data on 10,940 men and 35,147 women were obtained from the California Cancer Registry for 1988-2009. Population data were obtained from the 1990 and 2000 U.S. Census. Incidence rates and 95% confidence intervals (CI) were calculated and incidence trends were evaluated using Joinpoint regression to evaluate the timing and magnitude of change [annual percentage change (APC) and rate ratios].

resultsThe incidence of papillary thyroid cancer continues to increase in both men (APC, 5.4; 95% CI, 4.5-6.3 for 1998-2009) and women (APC, 3.8; 95% CI, 3.4-4.2 for 1998-2001 and APC, 6.3; 95% CI, 5.7-6.9 for 2001-2009). Increasing incidence was observed in all subgroups examined.

conclusionsAlthough some variation in the magnitude or temporality of the increase in thyroid cancer incidence exists across subgroups, the patterns (i) suggest that changes in diagnostic technology alone do not account for the observed trends and (ii) point to the importance of modifiable behavioral, lifestyle, or environmental factors in understanding this epidemic. IMPACT: Given the dramatic and continued increase in thyroid cancer incidence rates, studies addressing the causes of these trends are critical. Cancer Epidemiol Biomarkers Prev; 23(6); 1067-79. ©2014 AACR.

Indexed as

CaliforniaFemaleHumansIncidenceMaleThyroid Neoplasms

Identifiers

PMID24842625
PMCPMC4071298

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.